Reports Q4 revenue $311.1M, consensus $285.6M. “We are really pleased with our performance in the quarter and with the continued positive impact we make on patient care,” said Steve Chapman, CEO. “We believe we are in an excellent position to continue this momentum into 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James